UY32303A - Tiolactamas y sus usos - Google Patents

Tiolactamas y sus usos

Info

Publication number
UY32303A
UY32303A UY0001032303A UY32303A UY32303A UY 32303 A UY32303 A UY 32303A UY 0001032303 A UY0001032303 A UY 0001032303A UY 32303 A UY32303 A UY 32303A UY 32303 A UY32303 A UY 32303A
Authority
UY
Uruguay
Prior art keywords
tiolactamas
compounds
plk
inflammatory
inhibitors
Prior art date
Application number
UY0001032303A
Other languages
English (en)
Inventor
Tricia J Vos
Soucy Francois
Matthew O Duffey
Guo Jianping
Li Gang
Amy M Elder
Reynolds Dominic
Indu T Bharathan
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of UY32303A publication Critical patent/UY32303A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invención provee compuestos de fórmula I; en donde R1, R2, R3, R4, R5, y R6 son tal como se describieron en la memoria descriptiva. Los compuestos son inhibidores de la PLK y, por ende, son útiles para tratar trastornos proliferativos, inflamatorios o cardiovasculares.
UY0001032303A 2008-12-05 2009-12-07 Tiolactamas y sus usos UY32303A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20094508P 2008-12-05 2008-12-05

Publications (1)

Publication Number Publication Date
UY32303A true UY32303A (es) 2010-05-31

Family

ID=42076993

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032303A UY32303A (es) 2008-12-05 2009-12-07 Tiolactamas y sus usos

Country Status (7)

Country Link
US (6) US7998952B2 (es)
EP (1) EP2373657B1 (es)
JP (2) JP5684719B2 (es)
AR (1) AR074487A1 (es)
TW (1) TW201026703A (es)
UY (1) UY32303A (es)
WO (1) WO2010065134A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005294575B2 (en) * 2004-10-04 2011-11-24 Millennium Pharmaceuticals, Inc. Lactam compounds useful as protein kinase inhibitors
GB201604970D0 (en) 2016-03-23 2016-05-04 Syngenta Participations Ag Improvements in or relating to organic compounds
CN111763170B (zh) * 2020-07-10 2022-03-18 江苏豪森药业集团有限公司 氟马替尼中间体的制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06172355A (ja) 1992-04-14 1994-06-21 Mect Corp ピリミジン誘導体およびそれを有効成分とする血小板凝集阻止剤
DE4332168A1 (de) * 1993-02-22 1995-03-23 Thomae Gmbh Dr K Cyclische Derivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5686445A (en) * 1993-07-29 1997-11-11 American Cyanamid Company Pyridobenzoxazepine and pyridobenzothiazepine vasopressin antagonists
US5428040A (en) 1993-08-31 1995-06-27 The Du Pont Merck Pharmaceutical Company Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
US5925635A (en) * 1996-04-17 1999-07-20 Dupont Pharmaceuticals Company N-(amidinophenyl) cyclourea analogs as factor XA inhibitors
WO1997047601A1 (fr) 1996-06-11 1997-12-18 Yoshitomi Pharmaceutical Industries, Ltd. Composes heterocycliques fusionnes et leurs utilisations medicinales
WO1997047624A1 (en) 1996-06-13 1997-12-18 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US6057329A (en) * 1996-12-23 2000-05-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives
GB9713087D0 (en) * 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
FR2804959B1 (fr) * 2000-02-15 2006-04-28 Centre Nat Rech Scient Utilisation de derives de paullones pour la fabrication de medicaments
US6369222B1 (en) 2000-07-18 2002-04-09 Hoffmann-La Roche Inc. mGluR antagonists and a method for their synthesis
US6610677B2 (en) * 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7105667B2 (en) * 2001-05-01 2006-09-12 Bristol-Myers Squibb Co. Fused heterocyclic compounds and use thereof
WO2002088079A2 (en) 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
US6686352B2 (en) * 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
EP1552842A1 (en) 2002-06-07 2005-07-13 Kyowa Hakko Kogyo Co., Ltd. Bicyclic pyrimidine derivatives
EP1606268B1 (en) 2003-02-27 2015-05-20 AbbVie Inc. 5,10-dihydro-11h-dibenzo[b,e][1,4]diazepin-11-one as kinase inhibitors
DE602004023299D1 (de) * 2003-07-21 2009-11-05 Pfizer Prod Inc Nikotin abhängigkeit reduzierende heteroaryl kondensierte azapolycyclische verbindungen
CN1897950A (zh) * 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
ATE381566T1 (de) * 2004-05-14 2008-01-15 Millennium Pharm Inc Verbindungen und verfahren zur inhibierung der mitotischen progression durch hemmung von aurorakinase
AU2005294575B2 (en) * 2004-10-04 2011-11-24 Millennium Pharmaceuticals, Inc. Lactam compounds useful as protein kinase inhibitors
PE20070171A1 (es) 2005-06-30 2007-03-08 Boehringer Ingelheim Int GLICINAMIDAS SUSTITUIDAS CON EFECTO ANTITROMBOTICO E INHIBIDOR DEL FACTOR Xa
CL2007003244A1 (es) * 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.

Also Published As

Publication number Publication date
US20100179126A1 (en) 2010-07-15
US20110257157A1 (en) 2011-10-20
JP2012510990A (ja) 2012-05-17
US20150175542A1 (en) 2015-06-25
US20140194410A1 (en) 2014-07-10
EP2373657B1 (en) 2016-09-14
US20120309743A1 (en) 2012-12-06
JP2014221824A (ja) 2014-11-27
JP5684719B2 (ja) 2015-03-18
US8507667B2 (en) 2013-08-13
US8268992B2 (en) 2012-09-18
AR074487A1 (es) 2011-01-19
US20120302551A1 (en) 2012-11-29
US7998952B2 (en) 2011-08-16
EP2373657A1 (en) 2011-10-12
TW201026703A (en) 2010-07-16
WO2010065134A1 (en) 2010-06-10

Similar Documents

Publication Publication Date Title
CO6690755A2 (es) Heteroarilos como inhibidores de p13k
CR20110028A (es) Derivados de pirimidina como inhibidores de cinasa
EA201170252A1 (ru) Амидофеноксиндазолы в качестве ингибиторов c-мет
EP2603216A4 (en) HETEROARYLE AND USES THEREOF
CR20110032A (es) Derivados de tiofeno y tiazol y su uso como inhibidores de p13k
DOP2011000217A (es) Nuevas bencenosulfonamidas como bloqueadores de canales de calcio
DOP2013000036A (es) Derivados de ciclobutano como inhibidores de jak
CR20120158A (es) Compuestos de diòxido de iminotiadiazina como inhibidores de bace, composiciones y su uso.
DK2195015T3 (da) Sammensætning til behandling af prostatacancer
CR20160363A (es) Heteroarilos y usos de estos
GT200600035A (es) Aminopiridinas como inhibidores de beta-secretasa
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
DK3517534T3 (da) Forbindelser, der er anvendelige til behandling af cancer
EA201171367A1 (ru) Винилиндазолильные соединения
SV2011003809A (es) Derivados de heteroarilo como inhibidores de dgat1
ECSP11010770A (es) Compuesto heterocíclico y su uso
CR11488A (es) 4-fenilpiran 3,5-dionas, 4-feniltiopiran-3,5-dionas y 2-fenilciclohexan-1,3,5-trionas como herbicidas
CO6361937A2 (es) Derivados de heteroaril amidas y sus usos como activadores de glucoquinasa
DOP2013000082A (es) Heteroarilos y sus usos
CL2011000846A1 (es) Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
CR11416A (es) Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos
SV2009003373A (es) COMPUESTOS AMINO-5-[-4-(DIFLUOROMETOXI)FENIL SUSTITUIDO]-5- FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA REF. AM102759
EA201000219A1 (ru) Способ и композиция для лечения в-клеточных пролиферативных нарушений
CO6551705A2 (es) Derivados de 3.4.4a.10b- tetrahidro-1h-tiopirano-[4.3-c]- isoquinolina
BRPI0920728A2 (pt) Composição estabilizada para tratamento de psoríase

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181219